These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30032194)

  • 21. Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023.
    Chaix ML; Terracol L; Nere ML; Stefic K; Lascoux-Combe C; Manda V; Sellier P; Maylin S; Molina JM; Liegeon G; Delaugerre C; Salmona M
    J Med Virol; 2024 Oct; 96(10):e29948. PubMed ID: 39363782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fostemsavir: a first-in-class HIV-1 attachment inhibitor.
    Grant PM; Kozal MJ
    Curr Opin HIV AIDS; 2022 Jan; 17(1):32-35. PubMed ID: 34871189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
    Wang T; Ueda Y; Zhang Z; Yin Z; Matiskella J; Pearce BC; Yang Z; Zheng M; Parker DD; Yamanaka GA; Gong YF; Ho HT; Colonno RJ; Langley DR; Lin PF; Meanwell NA; Kadow JF
    J Med Chem; 2018 Jul; 61(14):6308-6327. PubMed ID: 29920093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
    Meanwell NA; Krystal MR; Nowicka-Sans B; Langley DR; Conlon DA; Eastgate MD; Grasela DM; Timmins P; Wang T; Kadow JF
    J Med Chem; 2018 Jan; 61(1):62-80. PubMed ID: 29271653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fostemsavir for the treatment of HIV.
    Seval N; Frank C; Kozal M
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):961-966. PubMed ID: 33331202
    [No Abstract]   [Full Text] [Related]  

  • 26. Recent research results have converted gp120 binders to a therapeutic option for the treatment of HIV-1 infection. A medicinal chemistry point of view.
    Governa P; Manetti F
    Eur J Med Chem; 2022 Feb; 229():114078. PubMed ID: 34992041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay.
    Gartland M; Zhou N; Stewart E; Pierce A; Clark A; Ackerman P; Llamoso C; Lataillade M; Krystal M
    J Antimicrob Chemother; 2021 Feb; 76(3):648-652. PubMed ID: 33241285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the Maraviroc-Resistant Mutation M434I in the C4 Region of HIV-1 gp120 on Sensitivity to Antibody-Mediated Neutralization.
    Boonchawalit S; Harada S; Shirai N; Gatanaga H; Oka S; Matsushita S; Yoshimura K
    Jpn J Infect Dis; 2016 May; 69(3):236-43. PubMed ID: 26166507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
    Thompson M; Lalezari JP; Kaplan R; Pinedo Y; Pena OAS; Cahn P; Stock DA; Joshi SR; Hanna GJ; Lataillade M;
    Antivir Ther; 2017; 22(3):215-223. PubMed ID: 27922453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotypic coreceptor analysis.
    Sierra S; Kaiser R; Thielen A; Lengauer T
    Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
    Kuhmann SE; Pugach P; Kunstman KJ; Taylor J; Stanfield RL; Snyder A; Strizki JM; Riley J; Baroudy BM; Wilson IA; Korber BT; Wolinsky SM; Moore JP
    J Virol; 2004 Mar; 78(6):2790-807. PubMed ID: 14990699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fostemsavir resistance-associated polymorphisms in HIV-1 subtype C in a large cohort of treatment-naïve and treatment-experienced individuals in Botswana.
    Zuze BJL; Radibe BT; Choga WT; Bareng OT; Moraka NO; Maruapula D; Seru K; Mokgethi P; Mokaleng B; Ndlovu N; Kelentse N; Pretorius-Holme M; Shapiro R; Lockman S; Makhema J; Novitsky V; Seatla KK; Moyo S; Gaseitsiwe S
    Microbiol Spectr; 2023 Dec; 11(6):e0125123. PubMed ID: 37823653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.
    Tebit DM; Patel H; Ratcliff A; Alessandri E; Liu J; Carpenter C; Plantier JC; Arts EJ
    AIDS Res Hum Retroviruses; 2016 Jul; 32(7):676-88. PubMed ID: 26861573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of polyanion-resistance on HIV-1 infection.
    Bobardt MD; Armand-Ugón M; Clotet I; Zhang Z; David G; Este JA; Gallay PA
    Virology; 2004 Aug; 325(2):389-98. PubMed ID: 15246277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
    Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
    Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
    Ray N; Harrison JE; Blackburn LA; Martin JN; Deeks SG; Doms RW
    J Virol; 2007 Apr; 81(7):3240-50. PubMed ID: 17251281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.
    Balzarini J; Van Laethem K; Daelemans D; Hatse S; Bugatti A; Rusnati M; Igarashi Y; Oki T; Schols D
    J Virol; 2007 Jan; 81(1):362-73. PubMed ID: 17050611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
    Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
    AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.